Flagship Pioneering 合并 Cellarity、Etiome 与 Empress Therapeutics 平台成立 Etcelera，以因果智能预测药物临床结局
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering 宣布将 Cellarity、Etiome 和 Empress Therapeutics 三家平台合并成立 Etcelera，整合转录组数据、化学蛋白质组学与扰动数据，并结合 Flagship 内部 AI 能力，在分子层面判定疾病因果、发现新靶点并开发小分子。
Etcelera unites the platform technologies of Cellarity, Etiome, and Empress Therapeutics with Flagship Pioneering's proprietary AI capabilities to scale causal intelligence in human biology
Veteran CEO and accomplished company builder Ad Rawcliffe to lead new entity
, /PRNewswire/ -- Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity1, Etiome, and Empress Therapeutics to pioneer causal intelligence in human biology: the ability to determine what truly drives disease and predict how a medicine will act in patients before it reaches the clinic. The company launches with continued support from Flagship Pioneering and others to scale the platform and advance drug discovery programs.
By combining high-resolution human transcriptomic data, advanced chemoproteomics, and state-of-the-art perturbation data generation, Etcelera's unified platform can elucidate cause and effect in disease at the molecular level. This, combined with Flagship's in-house AI capabilities, enables Etcelera to define novel targets and discover and develop small molecules against them with a greater probability of clinical success.
"Each of these foundational platforms has been a pioneer in its own right, advancing our understanding of human biology to inform drug discovery," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder of Etcelera. "Yet, the hardest problems in medicine don't yield to a single approach. The combined company, together with Flagship's in-house AI capabilities through our Pioneering Intelligence unit, has the cutting-edge AI tools, data, and expertise to tackle one of the biggest challenges in drug development."
The company launches with platform-derived programs in hematology (including myelofibrosis and essential thrombocythemia), metabolism (including partnered programs in MASH), and immunology. Its foundation is built on years of innovation at Cellarity, Etiome, and Empress Therapeutics, whose platforms were each originated in Flagship Labs to solve intractable problems. Cellarity pioneered reading and correcting the state of the whole cell, an approach that uncovered a new target and mechanism to switch on fetal hemoglobin in sickle cell disease and produced CLY-124, a clinical-stage small molecule program being advanced by a dedicated asset company2. Etiome's platform is the first to deliver temporal disease-stage intelligence, revealing the right stage and the right patients for intervention. Empress's industrialized multi-omics technology provides target or mechanism deconvolution and causal validation. Together, they form Etcelera's integrated platform, which builds on more than 20 years of combined data, including the largest foundation model in the industry trained on data from 150 million cells, and more than 30 proprietary, AI-powered prediction models to form an integrated drug discovery and development engine.
"Approximately 50 percent of drug candidates that reach Phase 2 fail because the industry lacks causal intelligence," said Alec Reynolds, Chairman of Etcelera and Senior Partner, Flagship Pioneering. "Etcelera will allow us to predict the clinical outcome before running the experiment. Our vision is to build a compounding AI system that becomes a definitive source of novel medicines that are more likely to succeed in clinical development than any prior technology."
"We can predict where a rocket will land, yet we still can't predict what a medicine will do in a patient," said Ad Rawcliffe, CEO of Etcelera and CEO-Partner, Flagship Pioneering. "Our goal at Etcelera is to decipher cause and effect in human biology and convert that understanding into more and better medicines for patients, and high-impact partnerships and data services."
About Etcelera
Etcelera is a drug discovery and development company moving the industry from probability to prediction. The company's causal biology platform combines high-resolution human transcriptomic data, advanced chemoproteomics, and large-scale perturbation data with AI-powered prediction models to determine cause and effect in disease, define novel targets, and advance novel small molecule programs with a greater probability of clinical success. A Flagship Pioneering company, Etcelera has programs in hematology, metabolism, and immunology and is based in Somerville, Mass. For more information, visit www.etcelera.com.
About Flagship Pioneering
Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, operating with $14 billion of assets under its direction as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including Generate Biomedicines, Inari, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health.
Contacts
1 Cellarity Platform, Inc.
2 Cellarity SCD, Inc.
SOURCE Flagship Pioneering
来源：PR Newswire Health · prnewswire.com